Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3477 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Micaela B Reddy und 21 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Oncology, Pfizer Inc., Boulder, Colorado, USA. Hauptthemen laut MEDLINE: Rifampin, Cytochrome P-450 CYP3A, Cytochrome P-450 CYP3A Inducers, Models, Biological. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Physiologically‐based pharmacokinetic (PBPK) modeling offers a viable approach to predict induction drug–drug interactions (DDIs) with the potential to streamline or reduce clinical trial burden if predictions can be made with sufficient confidence. In the current work, the ability to predict the effect of rifampin, a well‐characterized strong CYP3A4 inducer, on 20 CYP3A probes with publicly available PBPK models (often developed using a workflow with optimization following a strong inhibitor DDI study to gain confidence in fraction metabolized by CYP3A4, f m,CYP3A4 , and fraction available after intestinal metabolism, Fg), was assessed. Substrates with a range of f m,CYP3A4 (0.086–1.0), Fg (0.11–1.0) and hepatic availability (0.09–0.96) were included. Predictions were most often accurate for compounds that are not P‐gp substrates or that are P‐gp substrates but that have high permeability. Case studies for three challenging DDI predictions (i.e., for eliglustat, tofacitinib, and ribociclib) are presented. Along with parameter sensitivity analysis to understand key parameters impacting DDI simulations, alternative model structures should be considered, for example, a mechanistic absorption model instead of a first‐order absorption model might be more appropriate for a P‐gp substrate with low permeability. Any mechanisms pertinent to the CYP3A substrate that rifampin might impact (e.g., induction of other enzymes or P‐gp) should be considered for inclusion in the model. PBPK modeling was shown to be an effective tool to predict induction DDIs with rifampin for CYP3A substrates with limited mechanistic complications, increasing confidence in the rifampin model. While this analysis focused on rifampin, the learnings may apply to other inducers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Oncology, Pfizer Inc., Boulder, Colorado, USA.
- DMPK, Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co., Inc., Rahway, New Jersey, USA.
- DMPK, Janssen Pharmaceutica NV, A Johnson & Johnson Company, Beerse, Belgium.
- DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts, USA.
- Pharmacokinetics Dynamics and Metabolism, Pfizer Inc, Cambridge, Massachusetts, USA.
- DMPK, Pre-Clinical Sciences, Research Technologies, GSK, Stevenage, UK.
ORCID-Profile: Micaela B Reddy, Loeckie de Zwart, Diane Ramsden, Martin E Dowty, Kunal S Taskar, Jayaprakasam Bolleddula, Qiang Fu, Alix F Leblanc, Gareth Lewis, Neil Parrott, Venkatesh Pilla Reddy, Chandra Prakash, Kushal Shah, Dwaipayan Mukherjee, Jessica Rehmel, Niresh Hariparsad
Zitieren
APA
Reddy, M. B., Cabalu, T. D., de Zwart, L., Ramsden, D., Dowty, M. E., Taskar, K. S., Badée, J., Bolleddula, J., Boulu, L., Fu, Q., Kotsuma, M., Leblanc, A. F., Lewis, G., Liang, G., Parrott, N., Pilla Reddy, V., Prakash, C., Shah, K., Umehara, K., …, & Hariparsad, N. (2025). Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3477
Vancouver
Reddy MB, Cabalu TD, de Zwart L, Ramsden D, Dowty ME, Taskar KS, et al. Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3477
BibTeX
@article{Reddy2025,
author = {Reddy, Micaela B and Cabalu, Tamara D and de Zwart, Loeckie and Ramsden, Diane and Dowty, Martin E and Taskar, Kunal S and Badée, Justine and Bolleddula, Jayaprakasam and Boulu, Laurent and Fu, Qiang and Kotsuma, Masakatsu and Leblanc, Alix F and Lewis, Gareth and Liang, Guiqing and Parrott, Neil and Pilla Reddy, Venkatesh and Prakash, Chandra and Shah, Kushal and Umehara, Kenichi and Mukherjee, Dwaipayan and Rehmel, Jessica and Hariparsad, Niresh},
title = {Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3477}
}
EUVIMED